The latest update is out from Spyre Therapeutics (SYRE).
Spyre Therapeutics, Inc. has secured a significant deal with Paragon Therapeutics, granting them exclusive worldwide licenses to develop and commercialize certain antibodies, with milestone payments that could total up to $22 million for each research program. Additionally, they’ve appointed Dr. Sandra Milligan to their board, bringing her extensive experience in health and regulatory fields to the team. Stockholders showed strong support in their annual meeting, approving executive compensation and ratifying their current independent accounting firm. The company expects an increase in issued and outstanding shares following the conversion of Series B Preferred Stock, enhancing its financial structure for future growth.
For detailed information about SYRE stock, go to TipRanks’ Stock Analysis page.
